Rexulti vs Vraylar
Side-by-side cost comparison based on Medicare Part D data
Rexulti
Brexpiprazole
Manufactured by Otsuka
Vraylar
Cariprazine
Manufactured by AbbVie
Vraylar costs 3% less per claim than Rexulti ($383.00 vs $396.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Rexulti | Vraylar |
|---|---|---|
| Avg Cost Per Claim | $396.00 | $383.00 |
| Total Medicare Spending | $1.2B | $1.7B |
| Total Beneficiaries | 356,000 | 486,000 |
| Total Claims | 3,120,000 | 4,320,000 |
| Annual Cost/Patient | $3,466.00 | $3,403.00 |
| Year-over-Year Change | +22.4% | +26.3% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 17, 2029 |
| Manufacturer | Otsuka | AbbVie |
| Condition | Mental Health | Mental Health |
| Generic Name | Brexpiprazole | Cariprazine |
Rexulti vs Vraylar: What the Data Shows
Rexulti (Brexpiprazole) and Vraylar (Cariprazine) are both used to treat mental health. Based on Medicare Part D data, Vraylar costs $383.00 per claim, which is 3% less than Rexulti at $396.00 per claim.
Medicare spent $1.2B on Rexulti and $1.7B on Vraylar. In terms of patient reach, Vraylar serves more beneficiaries (486,000 vs 356,000).
Year-over-year spending changed +22.4% for Rexulti and +26.3% for Vraylar. Rexulti saw significant spending growth, suggesting increased utilization or price increases. Vraylar saw significant spending growth, suggesting increased utilization or price increases.
Rexulti has a generic available, while Vraylar remains brand-only until its patent expires Sep 17, 2029.
Frequently Asked Questions
Vraylar is cheaper at $383.00 per claim, compared to $396.00 for Rexulti. That makes Vraylar about 3% less expensive per claim based on Medicare Part D data.
Yes, both Rexulti and Vraylar are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Rexulti has a generic version (Brexpiprazole) available, which is typically much cheaper. Vraylar is currently brand-only, with patent expiring Sep 17, 2029.
Medicare Part D spent $1.2B on Rexulti covering 356,000 beneficiaries, and $1.7B on Vraylar covering 486,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.